Anti-TNF? to Delay or Prevent Progression to Stage 3 T1D
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetes Mellitus - Type 1
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Treatment assignment (active drug: placebo) will be assigned in a parallel, randomized, 1:1 model. Randomization will be conducted using block randomization with variable block sizes with stratification on TrialNet study site and age group (< 12 years old vs. 12 years old or older).Masking: Double (Participant, Investigator)Masking Description: Active drug and placebo will be identical in appearance and packagingPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 3 years and 46 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04729296
- Collaborators
- University of South Florida
- Investigators
- Study Chair: Carla Greenbaum, MD Type 1 Diabetes TrialNet
Get Well Soon